Industry / Poland
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
New Reimbursement List Contains No New Innovative Therapies
May 2008 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
In a further sign of the pro-generic policy being imposed by the Polish government, the recently formed list of drugs eligible for reimbursement contains no new innovative medicines. It is, however, claimed that the savings from increased use of the low cost alternative therapies will be reinvested in funding treatments for chronic diseases.